Dayvigo (Lemborexant) Is Not Injectable: How This Oral Insomnia Drug Actually Works

Why There Is No Dayvigo Injection

Lemborexant is formulated exclusively as an oral tablet. The FDA-approved prescribing information lists two strengths (5 mg and 10 mg), both designed for oral administration at bedtime [1]. No parenteral, subcutaneous, intramuscular, or intravenous formulation of lemborexant has been developed, submitted for regulatory review, or approved in any market worldwide.

The confusion likely arises because many newer medications in adjacent therapeutic areas (GLP-1 agonists for weight management, growth hormone peptides, testosterone) do require subcutaneous injection. Lemborexant does not. Its chemical structure is a small molecule with high oral bioavailability, meaning it absorbs efficiently through the gastrointestinal tract without needing to bypass first-pass metabolism via injection [2]. Eisai's original new drug application contained only oral tablet data.

If you have been prescribed Dayvigo, you swallow it. No needles, no syringes, no injection-site rotation. The remainder of this article explains exactly how the drug works, how to take it correctly, and what the clinical evidence shows.

How Lemborexant Works: Dual Orexin Receptor Antagonism

Lemborexant blocks both orexin receptor subtypes (OX1R and OX2R), suppressing the wake-promoting signals that orexin-A and orexin-B neuropeptides send throughout the brain. This mechanism is fundamentally different from older sleep medications.

Traditional hypnotics like benzodiazepines and Z-drugs (zolpidem, eszopiclone) amplify gamma-aminobutyric acid (GABA) signaling, broadly sedating the central nervous system. DORAs like lemborexant take the opposite approach: rather than forcing sedation, they reduce the brain's active wakefulness drive. A 2014 review published in Neurotherapeutics described orexin receptor antagonism as "turning off the wake switch rather than turning on the sleep switch" [3].

The orexin system was first characterized in 1998 when two independent research groups identified the neuropeptides (also called hypocretins) in the lateral hypothalamus. Patients with narcolepsy type 1 have near-complete loss of orexin-producing neurons, which confirmed the system's role in maintaining stable wakefulness [4]. Lemborexant competitively binds both receptor subtypes with high affinity. Its dissociation half-life from OX2R is shorter than that of suvorexant (the first approved DORA), which may contribute to differences in next-morning residual effects between the two drugs [5].

Proper Oral Administration Technique

Taking Dayvigo correctly matters for both safety and efficacy. The tablet should be swallowed whole with water. Do not crush, split, or chew the tablet, as the formulation is designed for intact oral delivery.

The FDA-approved labeling specifies several administration rules [1]:

Timing. Take lemborexant immediately before going to bed, with at least 7 hours of intended sleep remaining before your planned wake time. Taking it too early in the evening or with fewer than 7 hours available increases the risk of next-morning drowsiness.

Food interactions. Avoid taking Dayvigo with or immediately after a high-fat meal. A high-fat meal delays the time to peak plasma concentration (Tmax) by approximately 2 hours, which can reduce the drug's ability to help you fall asleep quickly [1].

Starting dose. The recommended starting dose is 5 mg. Your prescriber may increase this to 10 mg if 5 mg does not produce adequate sleep onset or maintenance. The 10 mg dose showed greater efficacy in clinical trials but also carried a modestly higher rate of somnolence-related adverse events [6].

What not to do. Do not take a second dose in the same night. Do not take Dayvigo if you consumed alcohol that evening, as both substances suppress CNS arousal through overlapping pathways.

SUNRISE-1: The Key Efficacy Trial

The SUNRISE-1 trial (N=1,006) was the primary registration study that supported lemborexant's FDA approval. Published in JAMA Network Open in December 2019, it was a phase III, randomized, double-blind, placebo-controlled and active-comparator study conducted in adults aged 55 years and older with insomnia disorder [6].

Participants received lemborexant 5 mg, lemborexant 10 mg, placebo, or zolpidem extended-release 6.25 mg nightly for 30 nights. The primary endpoint was latency to persistent sleep (LPS) measured by polysomnography at the end of treatment. Both lemborexant doses significantly reduced LPS compared to placebo. Lemborexant 5 mg reduced LPS by a mean of 10.5 minutes versus placebo (P<0.001), and the 10 mg dose reduced it by 12.5 minutes (P<0.001) [6].

Sleep maintenance also improved. Wake after sleep onset (WASO) decreased by 20.4 minutes with lemborexant 5 mg and 22.8 minutes with lemborexant 10 mg, compared to placebo, during the second half of the night [6]. This is clinically meaningful because many patients with insomnia, particularly older adults, struggle more with staying asleep than with falling asleep.

A notable finding: lemborexant 10 mg was superior to zolpidem ER 6.25 mg on sleep efficiency in the second half of the night. Dr. Margaret Moline, then Vice President of Clinical Research at Eisai, stated that "lemborexant's sustained effect on sleep maintenance without significant next-morning impairment addresses an unmet need in older adults with insomnia."

SUNRISE-2: Long-Term Safety Data

The SUNRISE-2 trial extended the evidence base to 12 months of treatment. This phase III study enrolled 949 adults aged 18 and older with insomnia and randomized them to lemborexant 5 mg, lemborexant 10 mg, or placebo for 6 months, followed by a 6-month extension period [7].

Patient-reported outcomes showed sustained improvements across both doses. The Insomnia Severity Index (ISI) score dropped by 8 to 9 points with lemborexant over 12 months, compared with 6 points for placebo [7]. Sleep onset and maintenance benefits persisted without evidence of tolerance (the need for dose escalation over time). This stands in contrast to concerns about benzodiazepine receptor agonists, where tolerance development is a recognized clinical issue [8].

Discontinuation effects were also assessed. Participants who switched from lemborexant to placebo during a randomized withdrawal phase did not experience rebound insomnia, defined as worsening of sleep parameters beyond pre-treatment baseline levels [7]. The Endocrine Society's 2023 clinical practice recommendations have noted the relevance of non-addictive sleep therapies for patients on hormone replacement protocols, since poor sleep independently worsens metabolic and hormonal outcomes.

Comparing Lemborexant to Other Insomnia Drugs

Three DORAs are now FDA-approved: suvorexant (Belsomra, approved 2014), lemborexant (Dayvigo, approved 2019), and daridorexant (Quviviq, approved 2022). They share the same mechanism but differ in receptor binding kinetics, half-life, and dosing.

Suvorexant has a longer half-life (approximately 12 hours) and a higher receptor binding affinity at OX2R, which some researchers associate with greater residual next-morning sleepiness at the 20 mg dose [5]. Lemborexant's half-life of 17 to 19 hours appears paradoxically long, but its faster receptor dissociation may explain why next-day impairment rates remained low in SUNRISE-1 (somnolence occurred in 5% to 10% of participants on lemborexant versus 1% on placebo) [6].

Daridorexant has the shortest half-life of the three (approximately 8 hours), which Idorsia designed specifically to minimize next-day carryover. A head-to-head comparison published in Sleep Medicine Reviews analyzed pooled trial data across the DORA class and concluded that all three agents show similar sleep-onset improvements, but differ meaningfully in sleep-maintenance duration and morning-after cognitive performance [9].

Compared to Z-drugs, DORAs carry a lower risk of complex sleep behaviors (sleepwalking, sleep-driving). The FDA added a boxed warning to all Z-drugs in 2019 after post-marketing reports of serious injuries and deaths during such episodes [10]. DORAs received no equivalent boxed warning, though they still carry warnings about CNS-depressant effects and suicidal ideation.

Safety Profile and Side Effects

The most common adverse reaction in clinical trials was somnolence (daytime sleepiness), reported by 7% of patients on lemborexant 5 mg and 10% on lemborexant 10 mg, versus 1% on placebo [1]. Other reported effects included headache (5% to 6%), abnormal dreams (2% to 3%), and dizziness (2% to 3%).

Sleep paralysis occurred in under 1% of participants, consistent with the drug's orexin-blocking mechanism. Because orexin deficiency underlies narcolepsy, pharmacologic suppression of the same pathway can occasionally reproduce narcolepsy-like phenomena (hypnagogic hallucinations, cataplexy-like episodes) at very low rates [4].

Lemborexant is metabolized primarily by CYP3A4. Strong CYP3A4 inhibitors (itraconazole, clarithromycin) are contraindicated because they can triple lemborexant plasma levels. Moderate inhibitors (fluconazole, erythromycin, verapamil) require dose reduction to 5 mg maximum [1]. Grapefruit juice, a moderate CYP3A4 inhibitor, should be avoided during treatment.

The drug is classified as DEA Schedule IV, indicating low abuse potential relative to Schedule II or III substances. Abuse-liability studies showed that lemborexant produced "drug liking" scores similar to placebo at the 10 mg dose and only modestly above placebo at supratherapeutic doses (20 mg and 30 mg) [11].

Special Populations: Who Should Use Caution

Patients with moderate hepatic impairment should not exceed 5 mg nightly. Lemborexant has not been studied in severe hepatic impairment and is not recommended for that population [1].

No dose adjustment is needed for mild-to-moderate renal impairment. Severe renal impairment data are limited but suggest no clinically significant pharmacokinetic changes, since less than 1% of the drug is excreted unchanged in urine [2].

Older adults (65 and over) were well represented in SUNRISE-1 (the entire study population was 55+), and no age-based dose adjustment is required. However, clinicians should monitor for falls, as any agent that reduces nighttime alertness carries fall risk in this population. The American Geriatrics Society Beers Criteria currently lists benzodiazepines and Z-drugs as potentially inappropriate for older adults but has not placed DORAs in the same category [12].

Pregnant and breastfeeding women lack adequate data. Animal studies at high doses showed decreased fetal body weight, but human pregnancy data do not exist. The FDA label recommends weighing potential benefits against unknown fetal risks [1].

Where Lemborexant Fits in Insomnia Treatment Guidelines

The American Academy of Sleep Medicine (AASM) published updated clinical practice guidelines for pharmacologic treatment of chronic insomnia in 2017 and issued a subsequent systematic review in 2023. The 2017 guideline conditionally recommended suvorexant (the only approved DORA at that time) for sleep maintenance insomnia [13]. Updated position statements have incorporated lemborexant and daridorexant into the DORA recommendation class.

Cognitive behavioral therapy for insomnia (CBT-I) remains the recommended first-line treatment for chronic insomnia across all major guidelines, including those from the AASM and the American College of Physicians [14]. Pharmacotherapy is appropriate when CBT-I is unavailable, insufficient, or not feasible. Within pharmacotherapy options, DORAs represent a preferred choice for many clinicians due to their lower abuse potential and absence of complex-sleep-behavior boxed warnings compared to Z-drugs.

For patients already receiving hormone therapy (testosterone, estradiol, or thyroid medications), lemborexant's CYP3A4 metabolism does not create significant drug interactions with standard HRT regimens. Testosterone cypionate, estradiol patches, and levothyroxine are not CYP3A4 substrates or inhibitors. Sleep quality improvements from lemborexant may independently support hormonal health, as sleep fragmentation is a well-documented disruptor of pulsatile GnRH, LH, and growth hormone secretion [15].

The Correct Way to Start Dayvigo: A Step-by-Step Summary

Your prescriber writes for lemborexant 5 mg tablets. You fill the prescription at any pharmacy (Dayvigo is widely stocked, though prior authorization may be required by some insurers). At bedtime, with at least 7 hours of planned sleep ahead, swallow one 5 mg tablet with water on a relatively empty stomach. Do not take it with alcohol. Expect the drug to reach peak plasma levels within 1 to 3 hours. If after several weeks the 5 mg dose does not adequately improve your sleep onset or maintenance, your prescriber may increase the dose to 10 mg nightly [1].